LGT Group Foundation’s Vertex Pharmaceuticals VRTX Stock Holding History

LGT Group Foundation’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.71M	Sell	3,840 -682	-15%	-$318K	0.02%	169
2025 Q4	$2.05M	Sell	4,522 -98	-2%	-$42.2K	0.02%	169
2025 Q3	$1.87M	Buy	4,620 +1,881	+69%	+$786K	0.02%	173
2025 Q2	$1.22M	Sell	2,739 -649	-19%	-$299K	0.02%	193
2025 Q1	$1.64M	Buy	3,388 +1,054	+45%	+$491K	0.02%	182
2024 Q4	$940K	Buy	2,334 +129	+6%	+$59.8K	0.01%	199
2024 Q3	$1.02M	Buy	+2,205	New	+$1.06M	0.02%	210
2023 Q4	–	Sell	-1,246	Closed	-$433K	–	268
2023 Q3	$433K	Buy	+1,246	New	+$436K	0.01%	221

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

LGT Group Foundation's VRTX Position: Q1 2026 in Review

LGT Group Foundation reduced its Vertex Pharmaceuticals (VRTX) stake by 15% in Q1 2026, selling an estimated $318K and leaving 3,840 shares worth $1.71M. The position accounts for 0.02% of the portfolio, ranked #169.

LGT Group Foundation first reported a position in VRTX in Q3 2023 and has held it in 8 quarters since. The position peaked at $2.05M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

LGT Group Foundation held 3,840 shares of Vertex Pharmaceuticals worth $1.71M as of Q1 2026.
LGT Group Foundation sold 682 Vertex Pharmaceuticals shares in Q1 2026, an estimated $318K.
Vertex Pharmaceuticals made up 0.02% of LGT Group Foundation's portfolio in Q1 2026, its #169 holding.
LGT Group Foundation first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
LGT Group Foundation's Vertex Pharmaceuticals position peaked at $2.05M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on LGT Group Foundation's 13F filing for Q1 2026, filed 28 Apr 2026.